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THIS PAPER concerns the design and inter-
pretation of animal tests for carcinogenicity
as one step which may or may not be deemed
necessary in the evaluation of chemical
substances for carcinogenicity. In designing
tests it has to be borne in mind that un-
treated control animals develop tumours-
sometimes in high incidence. Genetic factors,
oncogenic viruses and hormonal factors,
including those associated with overfeeding,
lack of stress, and sexdeprivation, are heavily
implicated in the aetiology of these back-
ground tumours. A cardinal principle of the
design of any meaningful test is that apart
from the variable under investigation, "like"
should be compared with "like", but it may
be difficult or impossible to put this principle
into practice. For example, inappetance
secondary to unpalatability of diet or in-
creasing nonspecific stress associated with
increasing dose may pose problems. Alter-
natively, the administration of a test agent
in high dosage may influence hormonal status
in a way which alters the risk of tumour
development or upsets the balance between
an oncogenic virus and its host. For these
reasons it is not justifiable to assume, as
some workers have, that an increased inci-
dence of any particular type of tumour indi-
cates that the test substance has induced the
extra tumours by reacting with cellular DNA
and thereby transforming normal cells to
cancer cells. In other words, an increased
incidence of tumours in a long-term animal
test does not constitute, by itself, enough
information for the purpose of assessing
carcinogenic hazard for man. For that pur-
pose information on likely mechanisms is
necessary, and it is particularly important to
see whether there is continuity or discon-
tinuity in response as one goes down the dose
scale. A substance which increases tumour
risk in a long-term animal test but gives
negative results in bacterial mutagenicity
tests may well be acting as a co-carcinogen
rather than a carcinogen in vivo, although
there are several alternative explanations of
such a combination offacts.
The objective of carcinogenicity tests
should be to obtain the information most
useful for assessing likely carcinogenic hazard
for man. For this purpose the dose range
should extend down to likely human exposure
levels, after taking into account absorption,
blood levels and other pharmacokinetic data.
Carcinogenicity tests confined to dose levels
close to maximum tolerated levels may
well give misleading positive results, since
they provide no information on possible
discontinuities in response with decreasing
dose.
As far as I am concerned, the more dose
levels studied the better, and I usually re-
commend the inclusion of two separate con-
trol groups in any carcinogenicity test which
is to be carried out for the purposes of safety
evaluation. I believe it is irrational to use
strains of rats and mice which are known to
be subject to high spontaneous tumour rates,
because to do so is to maximize the chances of
confusion due to co-carcinogenic effects in
such strains. I have been favourably impres-
sed by the suitability of the B6C3/1 hybrid
mice widely used for carcinogenicity testing
by the National Cancer Institute in its
Bioassay Programme. These hybrids appear
to be acceptably sensitive to known carcino-
gens, even though the incidence of "spon-
taneously-arising" neoplasms in controls is
relatively low. The Osborne-Mendel strain
ofrats used by the National Cancer Institute
appears to offer similar advantages.
Ordinarily, exposure to a test substance
should begin at weaning and continue
through life. Twice-daily surveillance, the
killing of sick animals, and a detailed and
standard necropsy are the key to meaningful
carcinogenicity tests. Tests should normally
continue until only, say, 20% of animals
survive in the group receiving the highest
tolerated dose level, but in this respect the
two sexes should be treated separately. I do
not like carcinogenicity tests involving
transplacental exposure, because of the logis-
tic problems they pose. Also, I know ofno
substance which has come to be regarded as
carcinogenically hazardous solely on the basis
of transplacental carcinogenicity.
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I do not believe that an increased incidence
of histologically benign tumours carries the
same weight or significance as an increased
incidence of malignant tumours. In any case,
the significance ofbenign tumours varies with
the organ affected. It is admittedly sometimes
difficult to distinguish benign from malignant
by simple microscopic examination. Never-
theless, I believe it is important to attempt
to do so, and regard it as scientifically repre-
hensible that it is now the policy in the USA
to regard all liver tumours in rats and mice
as malignant. This is a particularly foolish
decision since it can be difficult to distinguish
between benign tumours and islands of
altered liver cells. In most animal studies,
benign tumours far outnumber malignant
ones, but it is on the incidence of the latter
that assessments ofcarcinogenic potential for
man should be made.
Tumours differ in growth rate and poten-
tiality for causing ill-health or death. A
highly malignant tumour of the lymphoid
system in a mouse may progress from un-
detectability to lethality within a few weeks,
whereas a benign adenoma of the lung
appearing early in life may grow so slowly
that it has no effect on longevity. It is
important to distinguish between these two
types of tumour in the statistical evaluation
and assessment of the results of carcino-
genicity tests. Also, for clinically detectable
tumours, it is essential to keep detailed re-
cords ofthe time oftheir first appearance and
growth.
During recent years I have become in-
creasingly interested in, if not obsessed by,
the influence of what I regard as overfeeding
on tumour incidence. Mary Tucker at ICI
has shown that slight dietary restriction can
reduce the incidence ofall kinds ofneoplasm,
both benign and malignant, in laboratory
rats and mice by as much as 8-fold. Life-time
incidences of neoplasms are dramatically
reduced even though longevity is significantly
greater. Furthermore,throughout suchstudies
the animals appear healthier, sleeker and less
obese. Geoffrey Conybeare at the Smith,
Kline and French Laboratories, has obtained
similar findings in mice. I am convinced that
ad libitum feeding is unnatural, and totally
inappropriate for laboratory rats and mice in
carcinogenicity tests, and I cannot for the
life of me understand why the authorities in
theUSA consistently turn their back on these
facts. The position is that ad libitum feeding,
as compared with slightly restricted feeding,
can increase tumour incidence by far more
than would be necessary to lead to the
banning of a substance as a potent carcino-
gen. Despite this, no one has yet compared
the responses of ad libitum fed and restricted
fed animals to the same carcinogen in a
properly designed study over a suitable dose
range.
CAN STATISTICAL ANALYSES HELP THE UNDERSTANDING OF
LONG-TERM ANIMAL TESTS?
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